Jennifer Ringrose

Hydroxychloroquine-Induced Cardiomyopathy: Case Report, Pathophysiology, Diagnosis, and Treatment

Drug-induced heart and vascular disease remains an important health burden. Hydroxychloroquine and its predecessor chloroquine are medications commonly used in the treatment of systemic lupus erythematosus, rheumatoid arthritis, and other connective tissue disorders. Hydroxychloroquine interferes with malarial metabolites, confers immunomodulatory effects, and also affects lysosomal function. Clinical monitoring and early recognition of toxicity is an important management strategy in patients who undergo long-term treatment with hydroxychloroquine. Retinal toxicity, neuromyopathy, and cardiac disease are recognized adverse effects of hydroxychloroquine. Immediate withdrawal of hydroxychloroquine is essential if toxicity is suspected because of the early reversibility of cardiomyopathy. In addition to recommended ophthalmological screening, regular screening with 12-lead electrocardiogram and transthoracic echocardiography to detect conduction system disease and/or biventricular morphological or functional changes should be considered in hydroxychloroquine-treated patients. Cardiac magnetic resonance imaging and endomyocardial biopsy are valuable tools to provide prognostic insights and confirm the diagnosis of hydroxychloroquine-induced cardiomyopathy. In conclusion, chronic use of hydroxychloroquine can result in an acquired lysosomal storage disorder, leading to a drug-induced cardiomyopathy characterized by concentric hypertrophy and conduction abnormalities associated with increased adverse clinical outcomes and mortality.

Sleep Quality and Factors Influencing Self-Reported Sleep Duration and Quality in the General Internal Medicine Inpatient Population.

Background Sleep quality in hospitalized Canadian General Internal Medicine patients is not well characterized. Our goals were to characterize hospital sleep quality in this population and identify potentially modifiable barriers to good sleep. Methods GIM inpatients at a quaternary centre in Edmonton, Canada completed a survey, including the Verran-Snyder Halpern (VSH) questionnaire, to characterize the previous night’s sleep within 48 hours prior to discharge. A chart review was also completed to assess comorbidities, discharge diagnoses, and pharmaceutical sleep aid use. Results Patients reported significantly worse nighttime sleep duration in hospital compared with home (mean 5.5 versus 7.0 hours per night, p < 0.0001). Sleep quality was poor, as measured by the VSH disturbance (mean 371), effectiveness (190), and supplementation (115) subscales. Variables independently associated with poorer sleep duration in multivariable regression include prior diagnosis of sleep disorder and multi-patient occupancy rooms. Age, sex, admitting diagnosis, length of stay, frequency of vital checks, and use of sleep pharmaceuticals during the index hospitalization were not associated with sleep duration. The most frequently reported reasons for poor sleep included noise (59%), nursing interruptions (30%), uncomfortable beds (18%), bright lights (16%), unfamiliar surroundings (14%), and pain (9%). Conclusions Sleep quality for GIM inpatients is significantly worse in hospital than at home. There is a need to test non-pharmacologic interventions to address the most frequently identified factors causing poor sleep hygiene for GIM inpatients.

An Assessment of the Accuracy of Home Blood Pressure Monitors When Used in Device Owners

OBJECTIVE To examine the accuracy of home blood pressure (BP) devices, on their owners, compared to auscultatory reference standard BP measurements. METHODS Eighty-five consecutive consenting subjects ≥18 years of age, who owned an oscillometric home BP device (wrist or upper-arm device), with BP levels between 80-220/50-120 mm Hg, and with arm circumferences between 25-43 cm were studied. Pregnancy and atrial fibrillation were exclusion criteria. Device measurements from each subjects home BP device were compared to simultaneous 2-observer auscultation using a mercury sphygmomanometer. Between-group mean comparisons were conducted using paired t-tests. The proportion of patients with device-to-auscultatory differences of ≥5, 10, and 15 mm Hg were tabulated and predictors of systolic and diastolic BP differences were identified using linear regression. RESULTS Mean age was 66.4 ± 11.0 years, mean arm circumference was 32.7 ± 3.7 cm, 54% were female and 78% had hypertension. Mean BPs were 125.7 ± 14.0/73.9 ± 10.4 mm Hg for home BP devices vs. 129.0 ± 14.7/72.9 ± 9.3 for auscultation (difference of -3.3 ± 7.3/0.9 ± 6.1; P values <0.0001 for systolic and 0.17 for diastolic). The proportion of devices with systolic or diastolic BP differences from auscultation of ≥5, 10, and 15 mm Hg was 69%, 29%, and 7%, respectively. Increasing arm circumference was a statistically significant predictor of higher systolic (parameter estimate 0.61 per cm increase; P value 0.004) and diastolic (0.38; 0.03) BP. CONCLUSIONS Although mean differences from 2-observer auscultation were acceptable, when tested on their owners, most home BP devices were not accurate to within 5 mm Hg. Ensuring acceptable accuracy of the device-owner pairing should be prioritized.

The effect of back and feet support on oscillometric blood pressure measurements

Background/objective Recommendations to support the back and feet during blood pressure (BP) measurement are not always followed in clinical practice. Our objective was to determine to what extent back and feet support affects mean oscillometric BP measurements. Participants and methods Eighty-five consecutive, consenting participants 18 years or older with systolic BP readings 80-220 mmHg and diastolic BP readings 50-120 mmHg and arm circumferences of 25–43 cm were recruited. BP was measured using an Omron HEM 907 oscillometric device. Back and feet support were examined independently. First, while the feet were supported, two sets of three BP readings were taken in random order: one with the back supported and one with the back unsupported. Next, with the back supported, two sets of three BP readings were taken in random order: one with the feet dangling and one with feet supported. Results The mean age of the participants was 52.0±20.7 years and the mean arm circumference was 31.0±3.2 cm; 62% were women and 49% had hypertension. The mean BP levels with the back unsupported were slightly higher than those with the back supported (119.8±15.5/69.9±8.9 vs. 119.2±16.4/68.2±8.8 mmHg; difference of 0.7±4.9/1.8±3.0; P=0.21 for systolic and <0.0001 for diastolic comparisons). The mean BP levels with feet dangling were slightly lower than with feet supported (120.3±16.3/72.6±8.9 vs. 121.2±16.1/72.9±8.6 mmHg; difference of −0.9±4.1/−0.3±2.8; P=0.04 for systolic and <0.36 for diastolic comparisons). Systolic BP differences were greater than or equal to 5 mmHg in 34% (back phase) and 23% (feet phase) of the participants. Conclusion Provision of back and feet support has a small effect on the mean oscillometric BP. The magnitude of effect is greatest on diastolic BP when the back is unsupported.

Effect of Cuff Design on Auscultatory and Oscillometric Blood Pressure Measurements

BACKGROUND Two-piece blood pressure (BP) cuffs are the historical cuff standard. Use of 1-piece cuffs is increasing. Substituting 1-piece for 2-piece cuffs has an unknown effect on measurement accuracy. We compared these cuff types in a 2-phase study using auscultatory and oscillometric techniques. METHODS Consenting subjects (aged ≥18 years) with BP levels between 80 and 220mm Hg/50 and 120mm Hg and arm circumferences between 25 and 43cm were studied using the International Standards Organization (ISO) 2013 protocol (modified). A Baum 2-piece cuff was used as the reference standard. A 1-piece Welch Allyn cuff was the comparator. In phase 1 (2-observer auscultation with a mercury sphygmomanometer), 88 subjects were required to obtain 255 paired BP determinations. In phase 2 (oscillometric measurement with a Spacelabs 90207 device), 85 subjects were studied. Each phase was analyzed separately using paired t-tests. RESULTS Phase 1 mean age was 54.2±20.5 years, mean arm circumference was 29.9±3.7cm, 60% were female, and 32% had hypertension. One-piece cuff mean BPs were lower than the 2-piece cuff means (115.5±15.5/66.4±9.3 vs. 117.8±15.2/67.9±9.2; difference of -2.4±3.6/-1.5±2.4; P values <0.0001 for systolic and diastolic comparisons). Phase 2 mean age was 52.8±20.8 years, mean arm circumference was 29.4±3.9cm, 67% were female, and 38% had hypertension. Mean BPs were lower for the 1-piece compared to the 2-piece cuff (116.5±12.8/67.1±8.1 vs. 120.8±13.5/70.4±8.5; difference of -4.4±3.6/-3.3±2.7; P values <0.0001 for both). CONCLUSIONS Mean BP is lower with 1-piece cuffs vs. 2-piece cuffs. Differences are greater with oscillometry. When performing validation studies and measurements for clinical purposes, cuff type should be taken into account.

Should patients with higher blood pressure variability be excluded from validation studies? An assessment of the '12/8' rule.

To limit the inclusion of participants with increased blood pressure (BP) variability and presumably to avoid potential bias, the International Standards Organization BP device validation standard recommends exclusion of patients with a BP variability of more than 12/8 mmHg across reference readings. This ‘12/8 rule’ is based on expert consensus and lacks empirical justification. In a post-hoc analysis of a study comparing two types of cuff designs carried out according to the International Standards Organization standard, we divided the study sample into patients who did not have (n=79) and patients who had (n=55) more than 12/8 mmHg variability. Patients with more than 12/8 mmHg variability were older and had a higher prevalence of diabetes (41.8 vs. 22.8%; P=0.02) and hypertension (43.6 vs. 29.1%; P=0.08). The mean systolic BP differences between the two cuff designs were not significantly different in participants who did not show more than 12/8 mmHg variability versus those who did (2.2±3.5 vs. 3.1±3.4; mean difference of differences −0.9±3.4; P=0.14). Similarly, the mean diastolic BP differences were not significantly different in participants who did not have more than 12/8 mmHg variability versus those who did (1.5±2.2 vs. 1.4±2.6; mean difference of differences 0.1±2.4; P=0.82). A limitation of our analysis is that the original study data focused on a comparison of different cuff designs and not formal validation of a specific device. Therefore, replication of these findings is warranted. Nevertheless, our findings do not support the use of the 12/8 rule and indicate that this rule may be promoting unnecessarily homogenous study samples, limiting external generalizability, and needlessly increasing workload and expense.

Severe metabolic bone disease in pregnancy mimicking malignancy

A 21-year-old woman of El Salvadorian descent (born in El Salvador, with immigration to Canada at age three years), presented with a deformity of the right humerus in December, thought to have occurred following minor trauma. Radiography showed a fracture. She had a positive result on a pregnancy

Non-pharmacologic interventions to improve sleep of medicine inpatients: a controlled study

ABSTRACT Background: Sleep quality in hospitalized medicine patients is poor, with environmental factors among the most frequently cited reasons. Objective: We tested the efficacy of a non-pharmacologic intervention on the sleep quality of medicine inpatients. Design/Methods: A controlled study to evaluate our non-pharmacologic multidisciplinary ‘TUCK-in’ protocol (which includes timed lights-off periods, minimizing night-time noise, distribution of earplugs at bedtime, cued toileting before bedtime, and identification and reduction of modifiable interruptions) was deployed on two of five identical medicine wards. Randomization was at the level of the ward. The main outcome measure was self-reported duration of night-time sleep within 48 hours prior to discharge. Additional outcome measures included the Verran–Snyder-Halpern (VSH) Sleep Score and inpatient sleep pharmaceutical use. Results: Self-reported duration of night-time sleep (median 5.0 vs. 5.0 hours, p = 0.29) and daytime sleep (1.0 versus 0.5 hours, p = 0.43) did not differ between the 40 intervention patients and the 41 control patients (p = 0.13 on multivariate analysis). Cumulative VSH sleep disturbance (median 420 versus 359, p = 0.19), efficacy (median 169 versus 192, p = 0.29), or supplementation (median 97 versus 100, p = 0.51) scales were also not different between study arms. Conclusions: Although staff reported the protocol to be achievable and worthwhile, there were no significant differences in any of the outcomes between intervention and control patients.

Multifocal inflammatory demyelination in a patient with rheumatoid arthritis and treatment complications

Rheumatoid arthritis (RA) and multiple sclerosis (MS) are both autoimmune diseases that share similar pathogenesis, but the development of MS in RA patients without the treatment of anti-tumor necrosis factor-alpha is rarely reported, which might be attributed to the use of other medications with potential immunosuppressive effects in the treatment of RA. Since MS can be clinically silent and autopsy examination of the central nervous system in RA patients is rarely described, the association of MS with RA may be possibly under-recognized. We report an autopsy case revealing multifocal inflammatory demyelination in a RA patient who had a prolonged use of methotrexate and hydroxychloroquine resulting in hydroxychloroquine-induced myopathies and heart failure. The neuropathological features of this case are consistent with MS, although there are some altered inflammatory demyelinating features such as relatively smaller lesions and less infiltration of inflammatory cells, particularly T-cells. Our present case, in combination with literature review, suggests that the RA treatment especially with hydroxychloroquine and methotrexate is likely to alter the characteristics of inflammatory demyelination and disease course.